 | PYFA - Pyridam Farma Tbk | PYFA - Pyridam Farma Tbk | PYFA - Pyridam Farma Tbk | |
| Sector | : | Healthcare | ||
| Sub Sector | : | Pharmaceuticals and Health Care Research | ||
| Industry | : | Pharmaceuticals | ||
| Sub Industry | : | Pharmaceuticals | ||
| Index (4) | : | COMPOSITE, IDXHEALTH, IDXSMC-COM, DBX | ||
| Index (4) | : | COMPOSITE, IDXHEALTH, IDXSMC-COM, DBX | ||
| Board | : | 4 Index COMPOSITE, IDXHEALTH, IDXSMC-COM, DBX | ||
| Fasilitas Marjin | : | Saham yang tidak dapat diperdagangkan dengan menggunakan fasilitas marjin | ||
| Corporate Action | : | - | ||
| RATING & BTO MATRIX | ||||||
|---|---|---|---|---|---|---|
| Benchmark to Others : | ||||||
| A Exceptional | ||||||
| B Excellent | ||||||
| C Very Good | ||||||
| D Good | ||||||
| E Fair | |
|||||
| F Poor | ||||||
| RATING | ||||||
| RATING | 0 | 1 | 2 | 3 | 4 | 5 |
| RATING | 0 | 1 | 2 | 3 | 4 | 5 |
| RATING FUNDAMENTAL | ||
|---|---|---|
| Rating EPS | 0 | |
| Rating ROA | 1 | |
| Rating EQUITY | 2 | |
| Rating ROE | 0 | |
| Rating DER | 2 | |
| Rating TOTAL | 1 | |
| MARKET CAPITALIZATION | ||
| Listed Share | 11.236.680.000 | |
| Price | Rp. 260 | |
| Capitalization | Rp. 2.921.536.800.000 | |
| OWNERSHIP | ||
| Listing Date : 16-OCT-2001 | ||
| Lokal 35,18 % | Asing 64,82 % | Lainnya 0,00 % |
| PYFA - Pyridam Farma Tbk | PYFA - Pyridam Farma Tbk | PYFA - Pyridam Farma Tbk | |
| Sector | : | Healthcare | ||
| Sub Sector | : | Pharmaceuticals and Health Care Research | ||
| Industry | : | Pharmaceuticals | ||
| Sub Industry | : | Pharmaceuticals | ||
| Index (4) | : | COMPOSITE, IDXHEALTH, IDXSMC-COM, DBX | ||
| Index (4) | : | COMPOSITE, IDXHEALTH, IDXSMC-COM, DBX | ||
| Board | : | 4 Index COMPOSITE, IDXHEALTH, IDXSMC-COM, DBX | ||
| Fasilitas Marjin | : | Saham yang tidak dapat diperdagangkan dengan menggunakan fasilitas marjin | ||
| Corporate Action | : | - | ||
Financial Statements
| Description | 3Q18 | 3Q19 | 3Q20 | 3Q21 | 3Q22 | 3Q23 | 3Q24 | CAGR 5Y(%) |
| Last Price | 200 | 161 | 815 | 1150 | 910 | 805 | 302 | |
| Market Cap | 107.0 B | 86.1 B | 436.1 B | 615.3 B | 486.9 B | 430.7 B | 3.4 T | 3848.90 |
| BALANCE SHEET | ||||||||
| Cash | 1.5 B | 1.6 B | 3.7 B | 123.2 B | 123.5 B | 121.8 B | 505.4 B | 31487.50 |
| Total Asset | 187.5 B | 189.7 B | 218.6 B | 627.5 B | 1.5 T | 1.6 T | 5.9 T | 3010.17 |
| S.T.Borrowing | 35.0 B | 28.7 B | 36.9 B | 115.1 B | 271.4 B | 288.6 B | 2.3 T | |
| L.T.Borrowing | 39.3 B | 39.4 B | 40.9 B | 329.5 B | 789.5 B | 872.8 B | 2.4 T | |
| Total Equity | 113.2 B | 121.7 B | 140.8 B | 183.0 B | 456.0 B | 396.9 B | 1.2 T | 886.03 |
| INCOME STATEMENT | ||||||||
| Revenue | 185.5 B | 184.7 B | 195.3 B | 406.4 B | 550.9 B | 520.5 B | 1.2 T | 549.70 |
| Gross Profit | 113.7 B | 105.2 B | 117.6 B | 199.5 B | 183.7 B | 223.2 B | 295.8 B | 181.18 |
| Operating Profit | 8.0 B | 8.7 B | 22.2 B | 48.9 B | 346.1 B | 16.0 B | -112.8 B | -1396.55 |
| Net.Profit | 4.3 B | 4.9 B | 16.1 B | 16.0 B | 288.8 B | -53.2 B | -214.2 B | -4471.43 |
| EBITDA | 13.5 B | 14.2 B | 27.8 B | 54.5 B | 354.1 B | 26.3 B | -89.0 B | -726.76 |
| Interest Expense | 2.2 B | 2.1 B | 1.5 B | 28.1 B | 65.7 B | 63.9 B | 142.0 B | |
| RATIO | ||||||||
| EPS | 8.04 | 9.2 | 30.13 | 29.83 | 539.63 | -99.44 | -19.13 | -307.93 |
| PER | 24.88 x | 17.50 x | 27.05 x | 38.55 x | 1.69 x | -8.10 x | -15.79 x | |
| BVPS | 211.48 | 227.47 | 263.23 | 341.91 | 852.3 | 741.67 | 106.71 | |
| PBV | 0.95 x | 0.71 x | 3.10 x | 3.36 x | 1.07 x | 1.09 x | 2.83 x | |
| ROA | 0.0229 | 0.026 | 0.0737 | 0.0254 | 0.1904 | -0.0341 | -0.0364 | -240.00 |
| ROE | 0.038 | 0.0405 | 0.1145 | 0.0873 | 0.6332 | -0.1341 | -0.1787 | -541.23 |
| EV/EBITDA | 13.36 | 10.76 | 18.37 | 17.18 | 4.02 | 55.89 | -85.17 | |
| Debt/Equity | 0.66 | 0.56 | 0.55 | 2.43 | 2.33 | 2.93 | 3.91 | |
| Debt/TotalCap | 0.4 | 0.36 | 0.36 | 0.71 | 0.7 | 0.75 | 0.8 | |
| Debt/EBITDA | 5.52 | 4.8 | 2.8 | 8.15 | 3 | 44.15 | -52.73 | |
| EBITDA/IntExps | 6.04 | 6.75 | 18.38 | 1.94 | 5.39 | 0.41 | -0.63 | -109.33 |
| RATING & BTO MATRIX | ||||||
|---|---|---|---|---|---|---|
| Benchmark to Others : | ||||||
| A Exceptional | ||||||
| B Excellent | ||||||
| C Very Good | ||||||
| D Good | ||||||
| E Fair | |
|||||
| F Poor | ||||||
| RATING | ||||||
| RATING | 0 | 1 | 2 | 3 | 4 | 5 |
| RATING | 0 | 1 | 2 | 3 | 4 | 5 |
| MARKET CAPITALIZATION | ||
| Listed Share | 11.236.680.000 | |
| Price | Rp. 260 | |
| Capitalization | Rp. 2.922 B. | |
| OWNERSHIP | ||
| Listing Date : 16-OCT-2001 | ||
| Lokal 35,18 % | Asing 64,82 % | Lainnya 0,00 % |
| RATING FUNDAMENTAL | ||
|---|---|---|
| Rating EPS | 0 | |
| Rating ROA | 1 | |
| Rating EQUITY | 2 | |
| Rating ROE | 0 | |
| Rating DER | 2 | |
| Rating TOTAL | 1 | |
RETURN ON ASSET
| PYFA - Pyridam Farma Tbk | PYFA - Pyridam Farma Tbk | PYFA - Pyridam Farma Tbk | |
| Sector | : | Healthcare | ||
| Sub Sector | : | Pharmaceuticals and Health Care Research | ||
| Industry | : | Pharmaceuticals | ||
| Sub Industry | : | Pharmaceuticals | ||
| Index (4) | : | COMPOSITE, IDXHEALTH, IDXSMC-COM, DBX | ||
| Index (4) | : | COMPOSITE, IDXHEALTH, IDXSMC-COM, DBX | ||
| Board | : | 4 Index COMPOSITE, IDXHEALTH, IDXSMC-COM, DBX | ||
| Fasilitas Marjin | : | Saham yang tidak dapat diperdagangkan dengan menggunakan fasilitas marjin | ||
| Corporate Action | : | - | ||
| TIME PERIOD : 29-11-2024 | |||
| Close | 260 | Prev Close | 264 |
| Change | -4 (-1.5%) | Range | 256-274 |
| Bid | 258 | Offer | 260 |
| Bid Volume | 549500 | Offer Volume | 180600 |
| Frequency | 1775 | Value Rp.: 6.692.943.600 | |
| RETURN ON ASSET | |||||
|---|---|---|---|---|---|
| Benchmark to Others : | |||||
| A Exceptional | |||||
| B Excellent | |||||
| C Very Good | |||||
| D Good | |||||
| E Fair | |
||||
| F Poor | |||||
| RATIO (%) | ≤ 0 |
0-0.4 | 0.4- 1.7 |
1.7- 3.6 |
> 3.6 |
| RATING & BTO MATRIX | ||||||
|---|---|---|---|---|---|---|
| Benchmark to Others : | ||||||
| A Exceptional | ||||||
| B Excellent | ||||||
| C Very Good | ||||||
| D Good | ||||||
| E Fair | |
|||||
| F Poor | ||||||
| RATING | ||||||
| RATING | 0 | 1 | 2 | 3 | 4 | 5 |
| RATING | 0 | 1 | 2 | 3 | 4 | 5 |